Researchers developed and validated a new lung cancer prediction model, Sybil-Epi, by integrating clinical and epidemiologic data with a pre-existing model.
CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...
Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, ...
Re-prompting for ESR1 mutations in breast cancer: Improving mutation reporting and therapeutic decision-making. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This ...
The intersection of artificial intelligence (AI) and healthcare presents a transformative frontier, particularly in the global fight against cancer. As healthcare systems worldwide grapple with rising ...
New AI-driven systems for detecting and predicting gastrointestinal cancers have been developed through research projects in Singapore and South Korea. A research team from Singapore General Hospital ...
Low-dose computed tomography (LDCT) screening is effective in reducing lung cancer mortality by detecting the disease at earlier, more treatable stages. However, high false-positive rates and the ...
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...
A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results